Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.51 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | BRD4 | O60885 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.44 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2093768 | 0.89 | AOC3 (0.59) | AOC3L3MBTL1NPC1RAB9AALDH1A1 | |
| SCHEMBL27686957 | 0.84 | AOC3 (0.54) | AOC3L3MBTL1BRD4PKMCHRM2 | |
| SCHEMBL477338 | 0.84 | AOC3 (0.54) | AOC3L3MBTL1BRD4PKMCHRM2 | |
| SCHEMBL4822561 | 0.84 | AOC3 (0.54) | AOC3L3MBTL1NPC1RAB9ABRD4 | |
| SCHEMBL227352 | 0.83 | CES2 (0.55) | BRD4 | |
| SCHEMBL5359575 | 0.83 | NPC1 (0.45) | NFE2L2AOC3L3MBTL1NPC1RAB9A | |
| SCHEMBL17064980 | 0.83 | AOC3 (0.48) | NFE2L2AOC3L3MBTL1ALDH1A1BRD4 | |
| SCHEMBL31067553 | 0.83 | AOC3 (0.48) | NFE2L2AOC3L3MBTL1ALDH1A1BRD4 | |
| SCHEMBL31067514 | 0.81 | ALDH1A1 (0.66) | AOC3L3MBTL1NPC1RAB9AALDH1A1 | |
| SCHEMBL17064808 | 0.81 | ALDH1A1 (0.66) | AOC3L3MBTL1NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440690-B2 | Quinuclidine carbonate salts and medicinal composition thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-05-14 | — | — | US | disclosed |
| US-8404712-B2 | Quinuclidine carbonate salts and medicinal composition thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-03-26 | — | — | US | disclosed |
| EP-2313404-B1 | QUINUCLIDINE CARBONATE DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMA SPA (IT) | 2012-03-28 | — | — | EP | disclosed |
| US-20120004258-A1 | QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-01-05 | — | — | US | disclosed |
| US-20110319444-A1 | QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2011-12-29 | — | — | US | disclosed |
| US-8039483-B2 | Quinuclidine carbonate salts and medicinal composition thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2011-10-18 | — | — | US | disclosed |
| EP-2313404-A1 | QUINUCLIDINE CARBONATE DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMACEUTICI S.p.A. (IT) | 2011-04-27 | — | — | EP | disclosed |
| US-20100035922-A1 | QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2010-02-11 | — | — | US | disclosed |
| WO-2010015324-A1 | QUINUCLIDINE CARBONATE DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035922-A1 | QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF | CHRM3, CHRM2, CHRM4 | NFE2L2 3492/4885AOC3 1040/4885L3MBTL1 4577/4885 |
| US-20120004258-A1 | QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF | CHRM3, CHRM2, CHRM4 | NFE2L2 3492/4885AOC3 1040/4885L3MBTL1 4577/4885 |
| US-20110319444-A1 | QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF | CHRM3, CHRM2, CHRM4 | NFE2L2 3492/4885AOC3 1040/4885L3MBTL1 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.